{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"16"}],"units":"Participants"}],"description":"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. The number of participants who discontinued study treatment due to an AE is reported.","groups":[{"description":"V941(mRNA-5671/V941) 1 mg administered intramuscularly (IM) once every 3 weeks (Q3W) for 9 3-week cycles","id":"OG000","title":"Part 1: V941 Monotherapy"},{"description":"V941(mRNA-5671/V941) 1 mg administered IM Q3W for 9 3-week cycles and pembrolizumab 200 mg, intravenous (IV) for 35 3-week cycles","id":"OG001","title":"Part 1: V941 + Pembrolizumab"},{"description":"V941(mRNA-5671/V941) 1 mg administered IM Q3W for 9 3-week cycles and pembrolizumab 200 mg, IV for 35 3-week cycles","id":"OG002","title":"Part 2: Expansion Cohort 1 Non-small Cell Lung Cancer (V941 + Pembrolizumab)"},{"description":"V941(mRNA-5671/V941) 1 mg administered IM Q3W for 9 3-week cycles and pembrolizumab 200 mg, IV for 35 3-week cycles","id":"OG003","title":"Part 2: Expansion Cohort 2 Colorectal Cancer (V941 + Pembrolizumab)"},{"description":"V941(mRNA-5671/V941) 1 mg administered IM Q3W for 9 3-week cycles and pembrolizumab 200 mg, IV for 35 3-week cycles","id":"OG004","title":"Part 2: Expansion Cohort 3 Pancreatic Adenocarcinoma (V941 + Pembrolizumab)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who received at least 1 dose of study treatment. For AEs which occurred during Part 1 prior to switch-over, the information is in the Part 1: V941 Monotherapy column. For AEs which occurred during Part 1 subsequent to switch-over, the information is in the Part 1: V941 + Pembrolizumab column.","reportingStatus":"POSTED","timeFrame":"Up to approximately 24 months","title":"Number of Participants Who Discontinued Study Treatment Due to an AE","type":"PRIMARY","unitOfMeasure":"Participants"}